Biotinylated Human CCL5 (Rantes)
|
Stock Sizes: 2ug, 10ug, 50ug, 100ug, and 1mg
Also available in custom sizes, email for a custom quote. |
BACKGROUND
Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) (CCL5) is a proinflammatory chemokine that induces migration and activation of leukocytes, as well as implication in HIV infection. It binds to cell surface receptors CCR1, CCR3, CCR4, and CCR5. Its biological effects on leukocyte activation and HIV infection displays dependence on concentration and on the binding of cell surface glycosaminoglycans.
Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) (CCL5) is a proinflammatory chemokine that induces migration and activation of leukocytes, as well as implication in HIV infection. It binds to cell surface receptors CCR1, CCR3, CCR4, and CCR5. Its biological effects on leukocyte activation and HIV infection displays dependence on concentration and on the binding of cell surface glycosaminoglycans.
|
SPECIFICATIONS
Source: E. coli derived Accession # P13501 (24-91) Modification: Biotin at C-Terminal Formulation: Lyophilized Carrier Protein: None Predicted Molecular Mass: 10,269.7258 Da Extinction Coefficient: 18,020 M-1 cm-1 Actual Molecular Mass: 10,269.7258 Da by ESI Mass Spec Endotoxin Level: <0.01 EU per 1μg of the protein by the LAL method Purity: > 97% by SDS PAGE PREPARATION AND STORAGE Reconstitution: Spin sample prior to reconstitution. Recommended concentration of 100μg/mL in sterile water. Shipping: Room Temp Stability and Storage: Avoid repeated freeze-thaw cycles. • 12 months from date of receipt, -20 to -70 °C as supplied. • ChemoTactics suggests using immediately after reconstitution. • 1 month, -20 to -70 °C under sterile conditions after reconstitution. |
Migration Assay: Cells expressing recombinant CCR5 were assayed for migration through a transwell filter at various concentrations of WT Rantes or Biotinylated Rantes. Responses are expressed as the % of total input cells (Blue: wild type; Red: biotinylated).
Migration Assay Protocol 
Activity: EC50 = 0.25-0.50nM determined by Migration Assay of recombinant CCR5 containing cells
|
For bulk orders or custom sizes, please contact us and we can provide this for you.
|
|
|
|
|
|
REFERENCES
1. "The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5)"
Torretta S., Colombo G., Travelli C, Boumya S., Lim D., Genazzani A., Brolla A.
Cells 2020 Feb; 9(2):496. doi 10.3390/cells9020496 PMID: 32098202
2. “RANTES: a versatile and controversial chemokine”
Appay V., Rowland-Jones S.L.
Trends Immunol 22:83-87 (2001)
3. “Identification of RANTES, MIP-1, and MIP-1[1] as the major HIV-suppressive factors produced by CD8+T cells”
Cocchi F., De Vico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P.
Science 270:1811-1815 (1995)
4. A human T cell-specific molecule is a member of a new gene family
Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C., Davis M.M., Krensky A.M.
J Immunol 141:1018-1025 (1988)
5. “Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists”
Brandner B., Rek A., Diedrichs-Möhring M., Wildner G., Kungl A.J.
Protein Eng Des Sel. 22:367-373 (2009)
1. "The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5)"
Torretta S., Colombo G., Travelli C, Boumya S., Lim D., Genazzani A., Brolla A.
Cells 2020 Feb; 9(2):496. doi 10.3390/cells9020496 PMID: 32098202
2. “RANTES: a versatile and controversial chemokine”
Appay V., Rowland-Jones S.L.
Trends Immunol 22:83-87 (2001)
3. “Identification of RANTES, MIP-1, and MIP-1[1] as the major HIV-suppressive factors produced by CD8+T cells”
Cocchi F., De Vico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P.
Science 270:1811-1815 (1995)
4. A human T cell-specific molecule is a member of a new gene family
Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C., Davis M.M., Krensky A.M.
J Immunol 141:1018-1025 (1988)
5. “Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists”
Brandner B., Rek A., Diedrichs-Möhring M., Wildner G., Kungl A.J.
Protein Eng Des Sel. 22:367-373 (2009)
